Literature DB >> 31873844

A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.

Sebastián Udry1,2, José Omar Latino1, Cristina Belizna3,4, Silvia Perés Wingeyer2, Diego Santiago Fernández Romero1, Gabriela de Larrañaga5.   

Abstract

Extra-criteria manifestations such as thrombocytopenia and livedo are described associated with antiphospholipid syndrome (APS) but are not included in the current classification criteria. Their clinical expression might be important, as they may be associated with a high-risk profile of antiphospholipid antibodies (aPL) and thrombosis. We evaluated the association between the presence of extra-criteria manifestations in primary obstetric-APS (POAPS) and aPL profiles. We also evaluated whether the presence of extra-criteria manifestations in POAPS patients increases the risk of developing thrombosis during the follow-up period (median follow-up 5 years; range 3-9 years). We selected 79 women who were included in our study only if they were first diagnosed with POAPS (with no history of previous thrombosis) and reevaluated for the presence of thrombosis after the follow-up period. We evaluated the association between the aPL profile and extra-criteria manifestations. We also evaluated the relationship of thrombosis during the follow-up period with extra-criteria manifestations and other risk factors. Patients with three or more extra-criteria manifestations presented high rates of triple positivity for the aPL profile (75%) (p < 0.001). We also found a relationship between the presence of extra-criteria manifestations and the presence of high titers of aPL: 91.7% of patients with three or more extra-criteria manifestations had high titers of aPL (p < 0.01). We further evaluated the group of POAPS patients according to thrombotic events during the follow-up. Among these patients, 6 (7.6%) presented thrombosis. Notably, 100% of patients with a thrombotic event during the follow-up had more than three extra-criteria manifestations. POAPS patients with extra-criteria manifestations might have a high-risk aPL profile and a major risk of developing thrombosis.

Entities:  

Keywords:  Livedo reticularis; Pregnancy morbidity; Risk factor; Thrombocytopenia; Thrombosis

Mesh:

Substances:

Year:  2019        PMID: 31873844     DOI: 10.1007/s12026-019-09110-x

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  30 in total

1.  Are the cutaneous manifestations in patients with primary antiphospholipid syndrome a marker for predicting lung manifestations?

Authors:  Milica Kontic; Ljudmila Stojanovich; Milena Mijailović-Ivković; Mladen Velinović; Jasminka Srnka; Marija Zdravkovic
Journal:  Clin Exp Rheumatol       Date:  2017-07-17       Impact factor: 4.473

2.  Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases.

Authors:  Y Shen; X-W Chen; C-Y Sun; M Dai; Y-C Yan; C-D Yang
Journal:  Lupus       Date:  2010-05-26       Impact factor: 2.911

3.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

Review 4.  Clinical profiles and risk assessment in patients with antiphospholipid antibodies.

Authors:  Masaru Kato; Ryo Hisada; Tatsuya Atsumi
Journal:  Expert Rev Clin Immunol       Date:  2018-11-13       Impact factor: 4.473

5.  Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome.

Authors:  E Toubi; I Krause; A Fraser; S Lev; L Stojanovich; J Rovensky; M Blank; Y Shoenfeld
Journal:  Clin Exp Rheumatol       Date:  2005 Jul-Aug       Impact factor: 4.473

6.  Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome.

Authors:  I Krause; S Lev; A Fraser; M Blank; M Lorber; L Stojanovich; J Rovensky; J Chapman; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

7.  What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?

Authors:  Jose Omar Latino; Sebastián Udry; Silvia Perés Wingeyer; Diego Fernández Romero; Paula Micone; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

8.  Renal involvement in primary antiphospholipid syndrome.

Authors:  M C Amigo; R Garcia-Torres; M Robles; T Bochicchio; P A Reyes
Journal:  J Rheumatol       Date:  1992-08       Impact factor: 4.666

Review 9.  Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?

Authors:  Pier Luigi Meroni; Maria Orietta Borghi; Claudia Grossi; Cecilia Beatrice Chighizola; Paolo Durigutto; Francesco Tedesco
Journal:  Nat Rev Rheumatol       Date:  2018-07       Impact factor: 20.543

10.  Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study.

Authors:  G R de Jesús; S Sciascia; D Andrade; M Barbhaiya; M Tektonidou; A Banzato; V Pengo; L Ji; P L Meroni; A Ugarte; H Cohen; D W Branch; L Andreoli; H M Belmont; P R Fortin; M Petri; E Rodriguez; R Cervera; J S Knight; T Atsumi; R Willis; I S Nascimento; R Rosa; D Erkan; R A Levy
Journal:  BJOG       Date:  2018-10-24       Impact factor: 6.531

View more
  3 in total

1.  Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers-cross-sectional study of Serbian cohort.

Authors:  Aleksandra Djokovic; Ljudmila Stojanovich; Natasa Stanisavljevic; Sandra Djokic; Branka Filipovic; Predrag Matic; Milomir Milanovic; Svetlana Apostolovic; Jovica Saponjski
Journal:  Clin Rheumatol       Date:  2022-01-11       Impact factor: 2.980

Review 2.  An Update on Antiphospholipid Syndrome.

Authors:  Eleni Xourgia; Maria G Tektonidou
Journal:  Curr Rheumatol Rep       Date:  2022-01-05       Impact factor: 4.592

3.  Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome.

Authors:  Stanley Niznik; Micha J Rapoport; Orly Avnery; Aharon Lubetsky; Ronen Shavit; Martin H Ellis; Nancy Agmon-Levin
Journal:  Front Pharmacol       Date:  2022-04-21       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.